Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Rachel Leheny Insider Profile
4 Followers
Rachel Leheny, Director at Anthera Pharmaceuticals, holds 1.42M shares in Anthera Pharmaceuticals (Ticker: ANTH). Most recently, Rachel Leheny Bought $250,000 shares of Anthera Pharmaceuticals on Sep 24, 2010 for an estimated value of 750.00K.
Rachel Leheny has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Roles
Director
Roles that Rachel Leheny holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Sep 24, 2010 - Sep 24, 2011
Return:+16.10%
The most profitable trade made by Rachel Leheny
Rachel Leheny's Trading History
List of latest transactions for each holding click on a transaction to see Rachel Leheny's performance on stock
You May Also Like
Rachel Leheny insider profile FAQ
What is the percentage of profitable transactions made by Rachel Leheny?
The percentage of profitable transactions made by Rachel Leheny is ―.
What is the average return per transaction made by Rachel Leheny?
The average return per transaction made by Rachel Leheny is ―.
What stocks does Rachel Leheny hold?
Rachel Leheny holds: ANTH stocks.
What was Rachel Leheny’s latest transaction?
Rachel Leheny latest transaction was an Informative Buy of $750.00K.
What was Rachel Leheny's most profitable transaction?
Rachel Leheny’s most profitable transaction was an Informative Buy of ANTH stock on September 24, 2010. The return on the trade was 16.10%.
What is Rachel Leheny's role in Anthera Pharmaceuticals?
Rachel Leheny's role in Anthera Pharmaceuticals is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.